Deutsch English Français

Contact

EP3125894

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...

Extract from the Register of European Patents

EP About this file: EP3125894

EP3125894 - PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 16.07.2021 Database last updated on 08.04.2026
Former	The patent has been granted Status updated on 07.08.2020
Former	Grant of patent is intended Status updated on 26.03.2020
Former	Examination is in progress Status updated on 11.06.2019
Former	Request for examination was made Status updated on 06.01.2017
Former	The international publication has been made Status updated on 04.11.2016
Most recent event Tooltip	06.05.2022	Change - lapse in a contracting state State(s) deleted from list of lapses: AL	published on 08.06.2022 [2022/23]
Applicant(s)	For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US
	[2017/06]
Inventor(s)	01 / BURGEY, Christopher, S. 770 Sumneytown Pike West Point, Pennsylvania 19486 / US
	02 / FRITZEN, Jeffrey, F. 154 Micklitz Drive Pottstown, Pennsylvania 19464 / US
	03 / BALSELLS, Jaume 770 Sumneytown Pike West Point, Pennsylvania 19486 / US
	04 / PATEL, Mehul 770 Sumneytown Pike West Point, Pennsylvania 19486 / US
	[2017/06]
Representative(s)	Hussain, Deeba, et al Merck Sharp & Dohme (UK) Limited 120 Moorgate London EC2M 6UR / GB
	[N/P]
Former [2020/37]	Hussain, Deeba, et al Merck Sharp & Dohme Limited Hertford Road Hoddesdon Hertfordshire EN11 9BU / GB
Former [2017/06]	Buchan, Gavin MacNicol Merck Sharp & Dohme Limited European Patent Department Hertford Road Hoddesdon Hertfordshire EN11 9BU / GB
Application number, filing date	15774282.6	27.03.2015
	[2017/06]
	WO2015US22868
Priority number, date	US201461973689P	01.04.2014 Original published format: US 201461973689 P
	[2017/06]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2015153304
	Date:	08.10.2015
	Language:	EN
	[2015/40]
	Type:	A1 Application with search report
	No.:	EP3125894
	Date:	08.02.2017
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 08.10.2015 takes the place of the publication of the European patent application.
	[2017/06]
	Type:	B1 Patent specification
	No.:	EP3125894
	Date:	09.09.2020
	Language:	EN
	[2020/37]
Search report(s)	International search report - published on:	US	08.10.2015
	(Supplementary) European search report - dispatched on:	EP	10.11.2017
Classification	IPC:	A61K31/501, A61K31/506, A61K31/513, A61P31/18, C07D403/06, A61K45/06	[2017/50]
	CPC:	A61K31/506 (EP,KR,US); C07F9/6558 (RU); C07D403/06 (EP,KR,US); A61K31/501 (EP,US); A61K31/513 (EP,KR,US); A61K31/662 (RU); (+) A61K45/06 (EP,KR,US); A61P31/18 (EP,RU,US); C07D237/22 (US); C07D239/47 (US) (-)
	Former IPC [2017/06]	A61K31/501, A61K31/506, A61K31/513
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/06]
Extension states	BA	Not yet paid
	ME	Not yet paid
Validation states	MA	Not yet paid
Title	German:	PRODRUGS VON HIV-UMKEHRTRANSKRIPTASEHEMMERN	[2017/06]
	English:	PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS	[2017/06]
	French:	PROMÉDICAMENTS D'INHIBITEURS DE TRANSCRIPTASE INVERSE DE VIH	[2017/06]
Entry into regional phase	02.11.2016	National basic fee paid
	02.11.2016	Search fee paid
	02.11.2016	Designation fee(s) paid
	02.11.2016	Examination fee paid
Examination procedure	10.10.2016	Date on which the examining division has become responsible
	02.11.2016	Examination requested [2017/06]
	07.06.2018	Amendment by applicant (claims and/or description)
	14.06.2019	Despatch of a communication from the examining division (Time limit: M06)
	05.12.2019	Reply to a communication from the examining division
	27.03.2020	Communication of intention to grant the patent
	24.07.2020	Fee for grant paid
	24.07.2020	Fee for publishing/printing paid
	24.07.2020	Receipt of the translation of the claim(s)
Divisional application(s)	EP20194453.5 / EP3785714
Opposition(s)	10.06.2021	No opposition filed within time limit [2021/33]
Fees paid	Renewal fee
	07.03.2017	Renewal fee patent year 03
	08.03.2018	Renewal fee patent year 04
	08.03.2019	Renewal fee patent year 05
	10.03.2020	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	MC	09.09.2020
	SM	09.09.2020
	[2022/23]
Former [2021/45]	AL	09.09.2020
	MC	09.09.2020
	SM	09.09.2020
Former [2021/26]	AL	09.09.2020
	SM	09.09.2020
Former [2021/23]	SM	09.09.2020
Documents cited:	Search	[A] WO0003998 (NOVIRIO PHARMACEUTICALS LIMITE et al.) [A] 1-15 * claims 1, 9, 12 * * table 2 * * compound formula (A) *
		[A] US2005065145 (CAO SHELDON X et al.) [A] 1-15 * compounds formula (I), (II) * * claims 1, 248 *
	International search	[YA] US2013296382 (BURCH JASON et al.) [Y] 1, 3, 4/1, 4/3, 5/4/1, 5/4/3 * ; paragraphs [0018], [0493] *[A] 2, 4/2, 5/4/2, 9
		[YA] US2005215554 (DUNN JAMES P et al.) [Y] 1, 3, 4/1, 4/3, 5/4/1, 5/4/3 * ; paragraphs [0002], [0013], [0052], [0099] *[A] 2, 4/2, 5/4/2, 9
		[P,Y] WO2014058747 (MERCK SHARP & DOHME et al.) [P,Y] 1-3, 4/1-3, 5/4/1-3, 9 * ; entire document *
		[YA] JI, L ET AL.: "Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl) or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors", J. MED. CHEM., vol. 50, 2007, pages 1778 - 1786, XP055229210 [Y] 1, 3, 4/1, 4/3, 5/4/1, 5/4/3 * ; ; page 1778, column 1, paragraph 1; page 1778, column 2, Chart 1 * [A] 2, 4/2, 5/4/2, 9 DOI: http://dx.doi.org/10.1021/jm061167r
		[YA] LI, A ET AL.: "Novel Pyridinone Derivatives As Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTls) with High Potency against NNRTI-Resistant HIV-1 Strains", J. MED. CHEM., vol. 56, 2013, pages 3593 - 3608, XP055229212, Retrieved from the Internet [retrieved on 20150520] [Y] 1, 3, 4/1, 4/3, 5/4/1, 5/4/3 * ; abstract; page 3596, column 1, paragraph 4 - column 2, paragraph 1; page 3597, column 2, paragraphs 4-5; page 3598, column 1, paragraphs 2 and 4 [A] 2, 4/2, 5/4/2 DOI:* http://dx.doi.org/10.1021/jm400102x
	by applicant	WO2009067166
		WO2011126969
		WO0134578
		WO2004085406
		US7189718
		WO2005102989
		US7166738
		WO2006067587
		WO2007045572
		WO2007045573
		WO2008076225
		US2004192704
		US2007021442
		WO2007015812
		WO2011120133
		WO0003998
		US2005065145
		CLEMO ET AL., J. CHEM. SOC., 1954, pages 2693 - 2702
		SWEENEY ET AL., BIOORGANIC & MEDICINAL CHEM. LETTERS, vol. 18, 2008, pages 4348 - 4351
		"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
		"Remington - The Science and Practice of Pharmacy", 2012, PHARMACEUTICAL PRESS
		"Physicians' Desk Reference, Thomson PDR, Thomson PDR", 2003
		"Physicians' Desk Reference", 2014, PDR NETWORK

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.